Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 3
2(50.0%)
4Total
Phase 2(2)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03487549Phase 2Completed

Cantharidin and Occlusion in Verruca Epithelium

Role: collaborator

NCT03981822Phase 2Completed

A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts

Role: collaborator

NCT03377790Phase 3Completed

Cantharidin Application in Molluscum Patients-1

Role: collaborator

NCT03377803Phase 3Completed

Cantharidin Application in Molluscum Patients

Role: collaborator

All 4 trials loaded